Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006435 · ClinicalTrials.gov registry record
Study of Plexiform Neurofibromas in Neurofibromatosis Type 1
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 24
- Enrollment target
NCT00006435: Completed study, sponsored by National Cancer Institute (NCI).
NCT00006435 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006435 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
Background: -Plexiform neurofibromas in patients with NF1 are a significant cause of morbidity but little is known about the natural history of these lesions. Objectives: * The purpose of this study is to monitor the natural history of plexiform neurofibromas and to evaluate the usefulness of volumetric MRI tumor measurements in this disease. * Other goals of the study are to provide a body of normative data on the growth rate of plexiform neurofibromas and to establish a tissue repository and pathology review center to allow future studies of the pathogenesis of neurofibromas and clinical trials of potential therapeutic agents. Design \- This study is coordinated by Dr. Bruce Korf, and was initiated when he was at the Partners Center for Human Genetics, Boston, MA.
Primary Outcome
Monitor natural history of plexiform neurofibromas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2001-05-18 |
| Est. Completion | 2020-05-01 |
What the finished NCT00006435 record still lists
NCT00006435 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00006435 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006435 about?
NCT00006435 is a clinical study titled "Study of Plexiform Neurofibromas in Neurofibromatosis Type 1". Background: -Plexiform neurofibromas in patients with NF1 are a significant cause of morbidity but little is known about the natural history of these lesions. Objectives: * The purpose of this study is to monitor the natural history of plexiform neurofibromas and to evaluate the usefulness of vol...
What is the current status of trial NCT00006435?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2001-05-18. Estimated completion is 2020-05-01.
Who is sponsoring clinical trial NCT00006435?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI